BBCNEWS Click June 4, 2024 01:35:00
So we and others, over the last five to ten years, have developed a new viral vector, and we're manufacturing that here to deliver the genes we're delivering into the body. in addition, at meira, we've actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes that are delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to ...